{"preliminary_commentary":{"by_channel":{"x_thread":21,"youtube":14,"podcast":8},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03993912\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"IFM2017_03","nct_id":"NCT03993912","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ifm2017-03-nct03993912. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"IFM2017_03","arms":[{"description":"Daratumumab SC 1800 mg\n\n* once every week for 8 weeks\n* then once every other week for 16 weeks\n* thereafter once every 4 weeks, until progression Lenalidomide PO (25mg): days 1 through 21 of each 28-day cycle, until progression Dexamethasone PO (20mg): days 1, 8, 15, 22 of a 28-day cycle, for the first 2 cycles, then discontinued","label":"Arm 1: Experimental group","type":"EXPERIMENTAL"},{"description":"Lenalidomide PO (25mg): days 1 through 21 of each 28-day cycle, until progression Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression","label":"Arm 2: Control group","type":"SHAM_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-08-28","type":"ACTUAL"},"conditions":["Multiple Myeloma"],"enrollment":{"count":294,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Daratumumab SC in combination with Lenalidomide","otherNames":[],"type":"DRUG"},{"name":"Lenalidomide PO (25mg)","otherNames":[],"type":"DRUG"},{"name":"Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-23","lead_sponsor":"University Hospital, Lille","official_title":"A Phase III Study Comparing Lenalidomide and Subcutaneous Daratumumab (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd) in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2026-08-28","type":"ACTUAL"},"primary_outcomes":[{"measure":"Comparison of the efficacy of Daratumumab SC injection when combined with Lenalidomide (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd): PFS","timeFrame":"From date of randomization until the date of first documented progression or date of toxicity or date of death from any cause, whichever came first, assessed up to 84months"}],"references":[{"citation":"Manier S, Lambert J, Hulin C, Macro M, Laribi K, Araujo C, Pica GM, Touzeau C, Godmer P, Slama B, Karlin L, Orsini Piocelle F, Dib M, Sanhes L, Morel P, El Yamani A, Tiab M, Tabrizi R, Richez V, Garderet L, Royer B, Bareau B, Mariette C, Fleck E, Robu D, Calmettes C, Rigaudeau S, Demarquette H, Frenzel L, Decaux O, Mohty M, Arnulf B, Bigot N, Perrot A, Corre J, Mary JY, Avet-Loiseau H, Moreau P, Leleu X, Facon T. Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial. Lancet Oncol. 2025 Oct;26(10):1323-1333. doi: 10.1016/S1470-2045(25)00280-3.","pmid":"41038184","type":"RESULT"}],"start_date":{"date":"2019-10-17","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy","url":"https://clinicaltrials.gov/study/NCT03993912"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ifm2017-03-nct03993912"}